Kansas Patent of the Month – April 2023
Eir Pharmaceuticals, LLC, a development stage biotechnology company, has dedicated their expertise to developing products for both human and animal health. Recently, the company has been granted a patent for their topical cream formulation aimed at offering cosmetic, sun-protectant, wound treatment, and anti-scarring purposes.
There are, ofcourse, sun protectant and wound treatment creams all over the shelves. Eir Pharmaceuticals sets their cream apart from others by the use of a naturally occurring protein within the cream, derived from plants known to decrease inflammation, stimulate immune response and promote repair in damaged cells. This protein is known as the tripartite motif family of proteins (TRIM).
The cream formulation also includes an analgesic that mitigates pain during the healing process, making it perfect for patients who have undergone surgery, suffered injuries, or are suffering from skin diseases. The cream also contains inorganic salts that make it well-suited for use on open wounds on both human and animal skin.
Eir Pharmaceuticals has also developed a way to use this cream as a preventative for damage done to the skin due to exposure to the sun, protecting the skin from harmful UV rays. The company further claims the cream can be used to stimulate hair growth, increase energy production, and boost immunity.
This breakthrough product is the result of a long-standing problem in the industry. While existing methods for extracting key compounds for generating a chemical composition do exist, they have failed to adequately and reliably produce a chemical composition that has the results of Eir Pharmaceutical’s TRIM protein.
The cream formulation is stable and prevents degradation of the natural product extracts or TRIM proteins. Physicians can prescribe this cream to patients to expedite healing of wounds and reduce scarring.
Eir Pharmaceuticals pushes the boundaries of innovation in the medical industry with their groundbreaking research and development. The company’s proprietary biotechnology platform is designed to capture value across multiple markets, with applications for animal health, human consumer, and human health.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.